P-339 - Effect of lisdexamfetamine dimesylate on functional impairment in children and adolescents with attention-deficit/hyperactivity disorder
César A. Soutullo(The University of Texas Health Science Center), David Coghill(The University of Melbourne), Tobias Banaschewski(Heidelberg University), Michel Lecendreux(Laboratoire National de Référence), Ralph Bloomfield(AstraZeneca (United Kingdom)), P. Hodgkins(Takeda (United States))
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
|Cell|2019|1.5k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Attention-deficit/hyperactivity disorder
|Nature Reviews Disease Primers|2015|1.3k